EUVIMEDEUVIMED entdecken
Crossref

Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis

Thomas Graillon, Betty Salgues, Tatiana Horowitz, Laetitia Padovani, Romain Appay, Emeline Tabouret, Eric Guedj, Olivier Chinot

Journal of Neuro-Oncology · 2024

DOI: 10.1007/s11060-024-04622-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Thomas Graillon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Aix Marseille Univ, INSERM, APHM, MMG, UMR1251, Marmara Institute, La Timone Hospital, 264 rue Saint-Pierre, 13005, Marse…. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Several retrospective studies and meta-analyses of Peptide Radionuclide Radiation Therapy in meningiomas suggest six-month progression-free survival improvement for WHO grade 1 and 2 meningiomas. In the present study, we aimed to evaluate the impact of such treatment on three-dimensional volume growth rate (3DVGR) in nonanaplastic meningiomas. METHODS: The authors performed a retrospective study including eight patients treated with Lutathera®. Millimetric 3D T1-weighted with gadolinium enhancement magnetic resonance imaging sequences were requested for volume measurement. Then, tumor growth rate was classified following a previously described 3DVGR classification (Graillon et al.). RESULTS: Patients harbored seven WHO grade 2 meningiomas and one aggressive WHO grade 1. All patients, except one, underwent four treatment cycles. 3DVGR significantly decreased at 3, 6, and 12 months after treatment initiation analyzing each lesion separately. Mean and median 3DVGR from all patients were respectively at 29.5% and 44.5%/6 months before treatment initiation, then at 16.5% and 25%/6 months at three months post-treatment initiation, 9.5% and 4.5%/6 months after 6 months, as well as 9.5% and 10.5%/6 months after 12 months. At 3, 6, and 12 months after treatment initiation, 4/8, 6/7, and 5/6 patients were class 2 (stabilization or severe 3DVGR slowdown), respectively. No patient was class 1 at 6 and 12 months, suggesting a lack of drug response. CONCLUSION: In nonanaplastic meningiomas, Lutathera®'s antitumoral activity appeared delayed and more likely observed at six months, while no major response was observed under treatment. Moreover, its antitumoral activity persisted for 12-18 months following treatment initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMeningeal NeoplasmsNeoplasm Recurrence, LocalHumansRetrospective StudiesFemaleMaleMiddle AgedAgedAdultMagnetic Resonance ImagingFollow-Up StudiesPeptides

Stichwörter der Autor:innen

Growth rateLutathera®MeningiomaPeptide radionuclide radiation therapy

Substanzen

Peptides

Autor:innen und Institutionen

  • Department of Neurosurgery, Aix Marseille Univ, INSERM, APHM, MMG, UMR1251, Marmara Institute, La Timone Hospital, 264 rue Saint-Pierre, 13005, Marseille, France. tom.graillon@free.fr.
  • CERIMED, Nuclear Medicine Department, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, Aix-Marseille University, Marseille, France.
  • Radiotherapy Department, APHM, Timone Hospital, Marseille, France.
  • Service d'Anatomie Pathologique et de Neuropathologie, APHM, CHU Timone, Marseille, France.
  • Inst Neurophysiopathol, GlioME Team, Aix-Marseille Univ, CNRS, INP, PETRA network, Marseille, France.
  • Neuro-Oncology Department, APHM, Timone Hospital, Marseille, France.

Zitieren

APA

Graillon, T., Salgues, B., Horowitz, T., Padovani, L., Appay, R., Tabouret, E., Guedj, E., & Chinot, O. (2024). Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04622-5

Vancouver

Graillon T, Salgues B, Horowitz T, Padovani L, Appay R, Tabouret E, et al. Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04622-5

BibTeX
@article{Graillon2024,
  author = {Graillon, Thomas and Salgues, Betty and Horowitz, Tatiana and Padovani, Laetitia and Appay, Romain and Tabouret, Emeline and Guedj, Eric and Chinot, Olivier},
  title = {Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis},
  journal = {Journal of Neuro-Oncology},
  year = {2024},
  doi = {10.1007/s11060-024-04622-5}
}
Kostenlos starten →